EyeSense AG

Firmenbeschrieb

EyeSense AG is a venture-backed diagnostic device company based in Basel and with operations in Großostheim close to Frankfurt/ Main, Germany. EyeSense was founded in 2006 as a spin-out from CIBA Vision AG (a Novartis Company) and develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. In addition to glucose, the testing platform being developed by EyeSense has the potential to measure a broad variety of medical-relevant analytes in patients. Diabetes is an epidemically-growing disease with severe compliance issues in glucose monitoring as well as drug therapy for many patients. Though frequent glucose monitoring promises to reduce unwanted fluctuating glucose levels, the current painful, inconvenient finger-pricking methods are a major obstacle towards tight control due to patient aversion. Monitoring of glucose has been recognized as an important prerequisite for the prevention of severe damage caused by high blood glucose levels (cardiovascular disease, kidney failure, blindness). On the other hand, a reduction in long term damage through frequent glucose control and adequate therapy will lead to a significant reduction in healthcare system expenditures for diabetics